Answers are grounded in this paper and cite their sources.
Retrospective analysis reveals neutropenia during treatment suggests improved overall survival in advanced colorectal cancer.
Trifluridine/tipiracil is a standard treatment after the third-line treatment for advanced/recurrent colorectal cancer (CRC). This study aimed to clarify whether trifluridine/tipiracil-induced neutropenia (degree and time of onset) is predictive of better clinical outcomes in patients with CRC. We retrospectively identified 130 patients who received trifluridine/tipiracil for treating CRC at Ogaki Municipal Hospital (Ogaki, Japan) between July 2014 and July 2021. Kaplan-Meier and log-rank tests and multivariate analysis were performed to evaluate overall survival (OS) according to the degree and time of onset of neutropenia. The median OS of patients who developed Grade 1–2 neutropenia (n=27) and those who developed Grade 3–4 neutropenia (n=51) was 185 days (95% confidence interval [CI]: 154–223) and 279 days (95% CI: 214–301), respectively (log-rank test, p=0.002). The median OS of patients who developed ≥ Grade 3 neutropenia during the first course of treatment (n=25) and those who developed ≥ Grade 3 neutropenia after the second course (n=26) was 300 days (95% CI: 246–458) and 211 days (95% CI: 173–299), respectively (log-rank test, p =0.137). Compared with that of patients who did not develop neutropenia, the hazard ratio for death of patients who developed neutropenia during the first course of treatment was 0.608 (95% CI, 0.385–0.958; p =0.032). Although the timing of severe neutropenia during trifluridine/tipiracil administration was not related to OS, the presence or absence of neutropenia during the first course of trifluridine/tipiracil administration can predict prolongation of OS in patients with CRC.
No takes yet. Share an insight, caveat, or question.
Kimura et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: